NIH, NCI face devastating cuts in debt ceiling fight; We must rally for biomedical research

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

As members of the 118th Congress returned to Washington this week, everyone is focused on raising the nation’s debt limit, especially following Treasury Secretary Jane Yellen’s announcement that her agency would begin taking extraordinary measures to prevent the government from triggering a default. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Lisa M. Coussens, PhD
President, American Association for Cancer Research; Deputy director for basic & translational research, Knight Cancer Institute; Chair, Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University
Table of Contents

YOU MAY BE INTERESTED IN

In last week’s issue of The Cancer Letter, Jacquelyn Cobb, associate editor, wrote a story about the then-promising legislative package that was passed by the U.S. House of Representatives Jan. 22. At the time, the package was expected to pass in the Senate, provide funding for the federal government through fiscal year 2026, and prevent a government shutdown that looms Jan. 30. 
Lisa M. Coussens, PhD
President, American Association for Cancer Research; Deputy director for basic & translational research, Knight Cancer Institute; Chair, Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login